Reports are showing the clinical use of anti-PD-1/PDL-1 monoclonal antibodies in various cancers including melanomas and lung cancer (Sharma et al., 2011; Topalian et al., 2012), and in refractory Hodgkin's disease (Ansell et al., 2014). Here, PDCD1 is linked to cancer.